Aposcience AG products

Discussions are underway for the design of a clinical program in this indication together with a manufacturer of catheter devices suitable for direct myocardial injection of APO-1 (APOSEC^TM)

Aposcience AG will initiate a program to demonstrate safety and efficacy in this important indication with very large unmet medical need. The program consists of a phase I study in healthy volunteers, followed by a phase IIa study in a selected patient population. This program is designed to translate the extremely promising data from animal models into clinical practice.